Targets › PRKCA
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.
Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling…. (UniProt, P17252)
Open in Phaseline: the race on PRKCA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AdipoPharma | PATAS Trifluoroacetate Modulator of ALMS1-PKC alpha interaction | ALMS1, PRKCA | Phase 1 | Type 2 Diabetes | May 2027 |
Type 2 Diabetes (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.